Skip to content 
Freenome Holdings, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | 2.88M | 30.41M | [{"date":"2024-12-31","value":9.48,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Cost of Revenue | 2.56M | 1.94M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":75.82,"profit":true}] | |||
| Gross Profit | 318.00K | 28.46M | [{"date":"2024-12-31","value":1.12,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Gross Margin | 11.03% | 93.61% | [{"date":"2024-12-31","value":11.79,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Expenses | 294.86M | 253.88M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":86.1,"profit":true}] | |||
| Operating Income | (291.97M) | (223.47M) | [{"date":"2024-12-31","value":-29197300000,"profit":false},{"date":"2025-12-31","value":-22346900000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 17.55M | 4.13M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":23.51,"profit":true}] | |||
| Pre-Tax Income | (274.42M) | (219.34M) | [{"date":"2024-12-31","value":-27442100000,"profit":false},{"date":"2025-12-31","value":-21934300000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (274.42M) | (219.34M) | [{"date":"2024-12-31","value":-27442100000,"profit":false},{"date":"2025-12-31","value":-21934300000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (274.42M) | (219.34M) | [{"date":"2024-12-31","value":-27442100000,"profit":false},{"date":"2025-12-31","value":-21934300000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| FRNM | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| FRNM | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 30.96 |
| P/B | 0.00 |
| EV/R | 38.22 |
| EV/Ebitda | NM |
Freenome, Inc. Common stock (FRNM) share price today is $11.15
Yes, Indians can buy shares of Freenome, Inc. Common stock (FRNM) on Vested. To buy
Yes, you can purchase fractional shares of Freenome, Inc. Common stock (FRNM) via the Vested app. You can start investing in Freenome, Inc. Common stock (FRNM) with a minimum investment of $1.
You can invest in shares of Freenome, Inc. Common stock (FRNM) via Vested in three simple steps:
The 52-week high price of Freenome, Inc. Common stock (FRNM) is $14.26. The 52-week low price of Freenome, Inc. Common stock (FRNM) is $9.95.
The price-to-earnings (P/E) ratio of Freenome, Inc. Common stock (FRNM) is
The price-to-book (P/B) ratio of Freenome, Inc. Common stock (FRNM) is 0.00
The dividend yield of Freenome, Inc. Common stock (FRNM) is 0.00%
The market capitalization of Freenome, Inc. Common stock (FRNM) is $1.06B
The stock symbol (or ticker) of Freenome, Inc. Common stock is FRNM
Consider the share price of Freenome, Inc. Common stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Freenome, Inc. Common stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Freenome, Inc. Common stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Freenome, Inc. Common stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Freenome, Inc. Common stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Freenome, Inc. Common stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
